Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Function homology screening

a screening and function technology, applied in the field of function homology screening, can solve the problems of affecting the accuracy of the detection results, so as to enhance the response of the measured components and assess the effect of a perturbation on gene expression

Inactive Publication Date: 2008-03-13
DISCOVERYX CORP
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] Methods and compositions are provided for function homology screening by discriminating between different cellular pathways, both as to the effect of genotype modification on cellular pathways and changes in parameters resulting from changes in the pathways, and using the discrimination for determining the effect of an agent on a mammalian cell culture system simulating cellular functions, as in a cellular state of interest, usually associated with a diseased state of a mammalian host. Cells capable of responding to factors and simulating the state of interest are employed, where the factors enhance the response of the measured components of the phenotype to approximate the response in vivo to external agents. A sufficient number of factors are employed to involve a plurality of pathways and a sufficient number of parameters are selected to be involved with a plurality of pathways and provide a robust response to the effect of a change in the environment of the cells. A flexible, multiplex screening assay is provided for screening and biological activity classification of biologically active agents. Assays are performed in the presence of an agent of interest, whereby a level of at least about 3 markers is obtained associated with the presence of the agent and the results compared to the level of the markers observed in the absence of the agent. By employing reagents that are known to have an effect on a pathway in conjunction with the agent, the pathway affected by the agent can be determined. The data resulting from the assays can be processed to provide robust comparisons between different environments and agents. Databases are provided so that agents and their effects may be compared. Particularly, biomaps are provided allowing for ready comparison,—visual, mathematical and electronic—of the results of different assays involving the same or different agents with assays involving the same or different reagents.

Problems solved by technology

The explosion in numbers of potential new targets and chemical entities resulting from genomics and combinatorial chemistry approaches over the past few years has placed enormous pressure on screening programs.
The rewards for identification of a useful drug are enormous, but the percentage of hits from any screening problem are generally very low.
While collecting information about multiple aspects of pharmacologic activity is useful because it provides a more complete analysis of the compound, it also makes the data analysis more difficult, because multiple parameters must be considered.
While they have proven useful in many ways, however, transgenic animals frequently suffer from problems of time and expense, as well as compensatory mechanisms, redundancies, pleiotropic genetic effects, and the lethality of certain mutations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function homology screening
  • Function homology screening
  • Function homology screening

Examples

Experimental program
Comparison scheme
Effect test

example 1

Regulators of Endothelial Cell Responses to Inflammation

[0177] The present invention is useful for identifying regulators of inflammation using human endothelial cells as an indicator cell type. A set of assay combinations that reproduces aspects of the response of the endothelial cells to different types of inflammatory processes is developed in vitro.

[0178] Primary human umbilical vein endothelial cells (HUVEC) are used. Other cells that may replace HUVEC in the screen include primary microvascular endothelial cells, aortic or arteriolar endothelial cells or endothelial cell lines such as EAhy926 or E6-E7 4-5-2G cells or human telomerase reverse transcriptase-expressing endothelial cells (Simmons, J. Immunol., 148:267, 1992; Rhim, Carcinogenesis 19:673, 1998; Yang, J. Biol. Chem. 274:26141, 1999). 2×104 cells / ml are cultured to confluence in EGM-2 (Clonetics). Other media that may replace EGM-2 include EGM (Clonetics) and Ham's F12K medium supplemented with 0.1 mg / ml heparin and...

example 2

Multiplex Assay Combinations for Distinguishing Mechanism of Action

[0204] The following example demonstrates the utility of the invention in identification of the mechanism of action of a test compound or intervention identified in the optimized assay combination of Example 1. This assay combination is included in a panel that contains specific and targeted alterations. A neutralizing antibody to TNF-α was selected as a test agent, as it is active when tested in the optimized primary assay combination of Example 1 (FIG. 3A). When the test agent is evaluated in the panel of assay combinations, it can be determined if the active compound is acting on a component(s) unique to one receptor-stimulated pathway, or on a common pathway component or pathway activity. The neutralizing antibody to TNF-α as a test agent evaluated in these assay combinations alters the biomap, as shown in FIG. 3B.

[0205] Confluent cultures of HUVEC cells are treated with TNF-α (5 ng / ml), IFN-γ (100 ng / ml), IL-1...

example 3

Analysis in Multiplex Assay Combinations for Identifying Mechanism of Action

[0209] The following example demonstrates the usefulness of the present invention for identification of mechanism of action of a test agent selected as an active agent. A recombinant fusion protein containing the extracellular domains of the p55 TNF-α-receptor fused to immunoglobulin Fc domain (p55-Fc fusion protein) is selected as an active compound when tested in the optimized assay combination of Example 1 (FIG. 7A).

[0210] Confluent cultures of HUVEC cells are treated with TNF-α (5 ng / ml)+IFN-γ (100 ng / ml)+IL-1 (20 ng / ml) in the presence or absence of p55-Fc (50 ng / ml). After 24 hours, cultures are washed and evaluated for the cell surface expression of ICAM-1 (1), VCAM-1 (2), E-selectin (3), CD31 (4), and MIG (5) by cell-based ELISA performed as described in FIG. 1. The relative expression of each parameter is shown in FIG. 7A along the y-axis as average value of the OD measured at 450 nm of triplicate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.

Description

INTRODUCTION [0001] 1. Field of the Invention [0002] The field of the invention is the discrimination between different cellular pathways and their use in the determination of the effect of agents on cell cultures. [0003] 2. Background of the Invention [0004] Pharmaceutical drug discovery, a multi-billion dollar industry, involves the identification and validation of therapeutic targets, as well as the identification and optimization of lead compounds. The explosion in numbers of potential new targets and chemical entities resulting from genomics and combinatorial chemistry approaches over the past few years has placed enormous pressure on screening programs. The rewards for identification of a useful drug are enormous, but the percentage of hits from any screening problem are generally very low. Desirable compound screening methods solve this problem by both allowing for a high throughput so that many individual compounds can be tested; and by providing biologically relevant inform...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/02C12N15/09G01N5/00G01N33/15G01N33/50G01N33/68
CPCG01N5/00G01N2510/00G01N33/5023G01N33/5041G01N33/5044G01N33/5047G01N33/505G01N33/5061G01N33/5064G01N33/5091G01N33/6863G01N33/6866G01N33/6869G01N33/6872G01N2333/52G01N2333/70503G01N2500/10G01N33/5008C12Q1/06
Inventor BERG, ELLEN L.BUTCHER, EUGENE C.MELROSE, JENNIFER
Owner DISCOVERYX CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products